Welcome! Login | Register
 

“The Sunday Political Brunch”—March 26, 2017—“The Sunday Political Brunch” -- March 26, 2017

1st Annual Make Music Worcester to Debut in June—1st Annual Make Music Worcester to Debut in…

Museum of Russian Icons to Host Zolotoj Plyos Concert—Museum of Russian Icons to Host Zolotoj Plyos…

Worcester Regional Food Hub Names Rogers Kitchen Operations Manager—Worcester Regional Food Hub Names Rogers Kitchen Operations…

McGovern Says Passing Trumpcare “Requires Heart of Stone”—McGovern Says Passing Trumpcare "Requires Heart of Stone"

Leonard Moorehead, the Urban Gardener: Minor Spring Bulbs, Major Impact—Leonard Moorehead, the Urban Gardener: Minor Spring Bulbs,…

Man Charged With Murdering Father in Blackstone—Man Charged With Murdering Father in Blackstone

Auburn Man in Critical Condition Following Car Crash in Worcester—Auburn Man in Critical Condition Following Car Crash…

Fit For Life: Time for YOU!—Fit For Life: Time for YOU!

10 Great Things to do in Worcester This Weekend - March 24, 2017—10 Great Things to do in Worcester This…

 
 

AG Announces $68.5 Million Settlement with AstraZeneca

Friday, March 11, 2011

 

Attorney General Peter Kilmartin announced today that a $68.5 million dollar settlement has been reached with AstraZeneca Pharmaceuticals.

This settlement, which is the largest ever multi-state consumer protection-based pharmaceutical settlement, is expected to bring $908,838 to the state.

The settlement stems from a complaint alleging that AstraZeneca used deceptive practices to market the antipsychotic drug Seroquel for off-label uses, according to the Attorney General. The company was accused of withholding information on the drug’s dangerous potential side effects, in addition to the negative results of scientific study done that tested the safety of the drug.

“This settlement shows the commitment of this office to protect consumers from deceptive marketing and advertising practices by big pharmaceutical companies,” Kilmartin said.

Company promises changes

AstraZeneca has promised to alter the way that it markets Seroquel, eliminating the misleading practices in question. Along with the $68.5 million payment, under the settlement AstraZeneca must comply with provisions addressing numerous concerns that an extensive 3-year investigation yielded. For example, AstraZeneca must have policies in place to ensure that sales personnel do not promote to health care providers who are unlikely to prescribe Seroquel for an FDA-approved use.

Other states participating in the investigation and settlement were: Florida, Illinois, Arizona, California, Colorado, Connecticut, Delaware, Hawaii, Idaho, Iowa, Kansas, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Nebraska, Nevada, New Hampshire, New Jersey, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Vermont, Washington, West Virginia and Wisconsin.
 

 

Enjoy this post? Share it with others.

 
Delivered Free Every
Day to Your Inbox